Interestingly, we also preformed a pharmacological inhibition of CDK5 in HCT116 and SW480 cell lines with a specific CDK5 inhibitor roscovitine (ROS) and we found that treatment of ROS can dramatically decreased the ablitity of CRC cells in cell survival and migration (Supplementary Figure S1). This evidence concerns the gene CDK5 and colorectal carcinoma.